As use of immune checkpoint inhibitors (ICI) for various cancers increases, the number of patients presenting to the emergency department (ED) with associated immune-related adverse events (irAEs) will increase as well. This 1.0-hour, CME-certified program, presented by Drs. Christopher J. Coyne and Jayne Viets-Upchurch, will review the fundamentals of ICIs as used for cancer treatment, including standard-of-care regimens and the mechanisms of action for these agents.

Integrate patient-centered and evidence-based treatment options for rare cancers and blood disorders

The recent availability of PARP inhibitors as maintenance therapy in the first-line setting allows clinicians to offer improved treatment options to their patients with ovarian cancer.

This curriculum features expert commentaries and case discussions that synthesize data around PARP inhibition and its evolving place in the treatment of patients with prostate cancer.

Discuss the impact of cold agglutinin disease (CAD) on patients.

The first-line treatment of advanced NSCLC without actionable mutations has undergone a dramatic change over the last 5 years, with the standard of care changing from chemotherapy to immune checkpoint inhibitor (ICI) monotherapy for select patients, to a variety of ICI-based combination regimens in addition to monotherapy.

This activity has been designed to address the educational needs of community and academic physicians specializing in hematology and hematology/oncology. It will also benefit other clinicians who manage patients with Castleman disease (CD).